novel
subtyp
influenza
viru
pandem
influenza
viru
spread
worldwid
sinc
identifi
mexico
unit
state
march
april
garten
et
al
smith
et
al
b
initi
character
pandem
influenza
viru
isol
show
suscept
neuraminidas
inhibitor
nai
zanamivir
oseltamivir
resist
ion
channel
blocker
adamantan
smith
et
al
therefor
nai
especi
oseltamivir
pharmaceut
option
prophylact
drug
therapeut
drug
administ
individu
introduct
two
nai
clinic
use
low
rate
resist
virus
subtyp
strain
observ
influenza
season
monto
et
al
kramarz
et
al
tashiro
et
al
howev
influenza
season
novemb
season
influenza
virus
possess
substitut
neuraminidas
na
protein
histidin
tyrosin
residu
posit
isol
predominantli
eu
countri
influenza
season
virus
spread
dramat
worldwid
includ
japan
lackenbi
et
al
meijer
et
al
ujik
et
al
http
influenza
season
virus
spread
worldwid
replac
season
influenza
virus
virus
possess
substitut
na
protein
report
sporad
sever
countri
includ
japan
april
http
nai
surveil
japan
clinic
isol
sequenc
identif
substitut
marker
na
gene
virus
possess
substitut
found
april
http
virus
caus
local
epidem
japan
virus
isol
case
administ
prophylact
therapeut
point
oseltamivir
use
associ
emerg
virus
baz
et
al
current
detect
virus
japan
perform
partial
sequenc
na
gene
clinic
isol
identifi
substitut
marker
follow
na
inhibit
assay
use
chemiluminesc
system
method
howev
requir
skill
involv
labori
procedur
studi
monitor
rapidli
simpli
virus
possess
duplex
assay
assay
develop
use
endpoint
genotyp
analysi
method
assay
could
discrimin
viru
possess
mutat
clinic
specimen
rna
purif
requir
use
assay
detect
mutat
clinic
specimen
sinc
specimen
nasal
nasopharyng
swab
may
contain
compon
inhibit
reaction
assay
also
could
detect
mutat
clinic
isol
cultur
supernat
directli
without
rna
purif
sinc
rna
purif
procedur
sampl
increas
risk
abil
perform
assay
without
rna
purif
advantag
situat
larg
number
clinic
isol
handl
assay
develop
studi
use
tool
monitor
virus
nucleotid
sequenc
na
gene
virus
post
global
initi
share
avian
influenza
data
gisaid
databas
august
octob
align
use
clustal
w
softwar
larkin
et
al
base
sequenc
two
probe
detect
design
discrimin
c
nucleotid
posit
na
gene
respect
primer
probe
sequenc
list
tabl
influenza
virus
isol
clinic
specimen
use
canin
kidney
mdck
cell
caco
cell
human
colon
carcinoma
cell
type
subtyp
clinic
isol
determin
hemagglutin
inhibit
hi
test
clinic
isol
influenza
virus
includ
studi
cultur
passag
mdck
cell
mdck
cell
cultur
invitrogen
carlsbad
ca
contain
acetyl
trypsin
corp
st
loui
mo
penicillinstreptomycin
invitrogen
cytopath
effect
observ
hemagglutin
ha
assay
perform
use
turkey
red
blood
cell
ha
titer
confirm
higher
control
assay
suscept
nai
possess
resist
nai
possess
obtain
european
centr
diseas
prevent
control
ecdc
isol
patient
treatment
oseltamivir
respect
two
isol
use
control
assay
virus
use
studi
list
supplement
tabl
sever
subtypestyp
season
influenza
virus
use
valid
specif
assay
follow
viral
respiratori
pathogen
use
valid
specif
assay
follow
respiratori
syncyti
virus
b
human
parainfluenza
virus
human
rhinovirus
human
metapneumoviru
human
coronavirus
human
metapneumoviru
human
parainfluenza
virus
obtain
sendai
medic
center
human
rhinovirus
obtain
nagasaki
prefectur
institut
environment
research
public
health
respiratori
syncyti
virus
b
human
parainfluenza
virus
human
coronavirus
store
nation
institut
infecti
diseas
niid
nasal
pharyng
swab
collect
suspect
contact
case
influenza
suspend
viru
transport
medium
obtain
hospit
clinic
japan
specimen
collect
septemb
februari
studi
protocol
approv
ethic
committe
niid
studi
perform
complianc
declar
helsinki
inform
consent
obtain
patient
supernat
cultur
mdck
cell
inocul
influenza
virus
clarifi
centrifug
min
viral
rna
prepar
supernat
use
viral
rna
kit
qiagen
duesseldorf
germani
accord
manufactur
instruct
except
viral
rna
elut
ave
qiagen
total
rna
prepar
clinic
specimen
use
viral
rna
kit
qiagen
use
clinic
specimen
viral
isol
kit
ambion
austin
tx
use
clinic
specimen
kingfish
flex
thermo
fisher
scientif
waltham
accord
manufactur
instruct
total
rna
clinic
specimen
elut
ave
qiagen
wherea
total
rna
clinic
specimen
elut
elut
buffer
ambion
reaction
perform
use
viru
rox
vial
kit
qiagen
accord
manufactur
instruct
briefli
test
clinic
isol
use
cultur
medium
assay
contain
quantitect
viru
nr
master
mix
quantitect
viru
rt
mix
forward
primer
revers
primer
two
probe
probe
type
water
cultur
medium
test
clinic
specimen
use
extract
rna
rna
templat
use
cycl
perform
follow
min
activ
rt
follow
initi
denatur
min
subsequ
cycl
amplif
denatur
sec
anneal
well
extens
sec
use
roch
basel
switzerland
fluoresc
signal
collect
anneal
extens
step
amplif
data
endpoint
data
analyz
use
light
softwar
accord
manufactur
instruct
evalu
sensit
assay
influenza
viru
detect
assay
simplex
assay
design
type
assay
perform
use
previous
design
primer
probe
correspond
conserv
region
matrix
gene
segment
control
nakauchi
et
al
confirm
subtyp
influenza
viru
clinic
specimen
test
simplex
assay
detect
specif
viru
assay
describ
previous
nakauchi
et
al
amplifi
partial
na
gene
start
codon
use
extract
rna
isol
viru
carri
follow
pair
primer
swine
swine
tabl
use
rna
pcr
kit
amv
takara
tokyo
japan
accord
manufactur
instruct
condit
follow
min
activ
rt
follow
initi
denatur
min
subsequ
cycl
amplif
denatur
sec
anneal
sec
extens
min
pcr
product
purifi
sequenc
use
swine
primer
bigdy
termin
cycl
sequenc
kit
appli
biosystem
carlsbad
ca
appli
biosystem
dna
analyz
total
rna
prepar
describ
rna
prepar
section
specif
duplex
endpoint
genotyp
assay
detect
viru
evalu
use
human
season
influenza
virus
influenza
b
virus
viral
respiratori
pathogen
assay
react
specif
virus
show
subtypestyp
influenza
b
virus
viral
respiratori
pathogen
data
shown
sensit
assay
compar
type
assay
use
serial
dilut
pdm
pdm
virus
six
replic
assay
shown
tabl
ii
minimum
viral
titer
detect
pdm
pdm
use
type
assay
respect
endpoint
fluoresc
plot
fig
standard
curv
type
assay
also
gener
fig
c
standard
curv
show
linear
relationship
log
viral
titer
cross
point
cp
valu
fig
fig
correl
coeffici
standard
curv
indic
precis
relationship
viral
titer
cp
valu
fig
c
octob
februari
clinic
specimen
nasal
pharyng
swab
nasal
aspir
suspect
case
viru
infect
n
obtain
hospit
clinic
japan
clinic
specimen
test
type
assay
rna
purif
clinic
specimen
clinic
specimen
confirm
posit
type
clinic
specimen
confirm
neg
type
tabl
iii
type
clinic
specimen
test
assay
specimen
determin
specimen
determin
tabl
iii
five
type
clinic
specimen
confirm
neg
assay
tabl
iii
result
also
shown
endpoint
fluoresc
plot
fig
facilit
assay
scheme
assay
perform
use
cultur
supernat
infect
mdck
cell
directli
without
rna
purif
templat
assay
screen
mutat
larg
number
clinic
isol
clinic
isol
possess
clinic
isol
possess
clinic
isol
combin
virus
possess
use
directli
valid
assay
without
rna
purif
three
isol
season
influenza
virus
possess
three
isol
season
influenza
virus
possess
also
use
directli
neg
control
assay
without
rna
purif
isol
season
influenza
virus
show
neg
assay
fig
assay
isol
virus
possess
confirm
fig
result
clinic
isol
shown
fig
respect
four
clinic
isol
combin
virus
confirm
mix
fig
studi
rapid
simpl
duplex
endpoint
genotyp
assay
discrimin
virus
possess
mutat
assay
develop
sensit
assay
compar
type
assay
tabl
ii
detect
limit
copiesreact
nakauchi
et
al
nonspecif
reaction
observ
assay
perform
use
subtypestyp
influenza
virus
fig
clinic
specimen
tabl
iii
fig
result
demonstr
assay
highli
specif
sensit
detect
mutat
use
assay
purifi
rna
clinic
specimen
test
tabl
iii
fig
clinic
specimen
test
posit
type
tabl
iii
fig
among
specimen
assay
detect
virus
viru
result
correspond
na
sequenc
discrep
assay
na
sequenc
suggest
assay
could
discrimin
virus
possess
clinic
specimen
clinic
isol
cultur
supernat
mdck
cell
fig
use
directli
assay
without
rna
purif
assay
result
compar
result
na
sequenc
discrep
found
assay
data
shown
sequenc
data
na
gene
clinic
isol
use
studi
deposit
gisaid
databas
four
clinic
isol
fig
found
mix
popul
virus
possess
sequenc
na
gene
data
shown
detect
mix
assay
fig
result
suggest
assay
could
discrimin
specif
virus
possess
mix
noteworthi
assay
could
detect
mutat
clinic
isol
without
rna
purif
sinc
suffici
amount
viral
rna
may
releas
virion
rt
condit
min
consid
handl
larg
number
clinic
isol
assay
perform
rapidli
simpli
lower
risk
rna
purif
unnecessari
recent
assay
develop
use
probe
contain
lna
nucleotid
discrimin
possess
van
der
vri
et
al
assay
highli
specif
result
interpret
easili
howev
viru
evalu
assay
two
assay
also
develop
one
detect
virus
possess
detect
possess
hindiyeh
et
al
howev
two
independ
assay
describ
discrimin
simpl
interpret
result
costli
assay
develop
studi
could
perform
rapidli
simpli
sinc
cultur
supernat
infect
cell
use
directli
without
rna
purif
fig
endpoint
genotyp
analysi
program
light
softwar
interpret
result
assay
automat
use
posit
control
like
pdm
pdm
suggest
assay
use
screen
mutat
nai
surveil
activ
addit
assay
could
detect
whether
patient
infect
virus
test
clinic
specimen
suggest
assay
power
diagnost
method
determin
manag
patient
